Solution for Injection/Infusion
Consumer Medicine Information
What is in this leaflet
This leaflet answers some common questions about Praxbind.
It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.
All medicines have risks and benefits. Your doctor has weighed the risks of you using Praxbind against the benefits they expect
it will have for you.
If you have any concerns about being treated with this medicine, ask your doctor.
This leaflet was last updated on the date at the end of this leaflet. More recent information may be available. The latest
Consumer Medicine Information is available from your pharmacist, doctor, or from www.medicines.org.au and may contain important
information about the medicine and its use of which you should be aware.
Keep this leaflet.
You may need to read it again.
What Praxbind is used for
Praxbind contains the active substance idarucizumab and is a reversal agent specific for Pradaxa (dabigatran etexilate), a
blood thinner medicine that blocks a substance in the body, which is involved in blood clot formation. Praxbind is used to
rapidly trap dabigatran in order to inactivate its effect.
Praxbind is used in emergency situations where your doctor decides that rapid inactivation of the effect of Pradaxa (dabigatran
etexilate) is required such as:
for emergency surgery/urgent procedures
in life-threatening or uncontrolled bleeding.
This medicine will only remove dabigatran from your body. It will not remove other medicines used to prevent the formation
of blood clots.
After dabigatran has been removed from your body, you are not protected from the formation of blood clots. Your doctor will
continue treating you with medicines used to prevent the formation of blood clots as soon as your medical condition allows.
Ask your doctor if you have any questions about why this medicine is being given to you.
Your doctor may have prescribed it for another reason.
Before you are given Praxbind
When you must not be given it
Praxbind must not be used after the expiry date printed on the pack or vial or if the packaging is torn or shows signs of
If you are not sure whether you should be given this medicine, talk to your doctor.
Before you are given it
Tell your doctor if you:
are allergic to any medicine containing idarucizumab or any of the ingredients listed at the end of this leaflet. Some of
the symptoms of an allergic reaction may include shortness of breath, wheezing or difficulty breathing, swelling of the face,
lips, tongue or other parts of the body, rash, itching or hives on the skin.
have a genetic disease called hereditary fructose intolerance. In this case, the substance sorbitol contained in Praxbind
may cause serious adverse reactions.
are on a sodium restricted diet. Praxbind contains 50 mg sodium per dose.
Your doctor will take this into account before treating you with Praxbind.
Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.
Tell your doctor if you are pregnant or plan to become pregnant or are breastfeeding.
Your doctor can discuss with you the risks and benefits involved.
If you are uncertain as to whether you have, or have had, any of these conditions you should raise those concerns with your
If you have not told your doctor about any of the above, tell him/her before you are given Praxbind.
Children and adolescents
There is no information on the use of Praxbind in children.
Taking other medicines
Tell your doctor if you are taking any other medicines, including any that you get without a prescription from your pharmacy,
supermarket or health food shop.
This medicine has been designed to only bind to dabigatran. It is unlikely that other medicines will influence the effect
of Praxbind or that Praxbind will influence the effect of other medicines.
How Praxbind is given
How much is given
The recommended dose of Praxbind is 5 g (2 vials of 50 mL).
In rare cases you may still have too much dabigatran in your blood after a first dose of Praxbind and your doctor may decide
to give you a second 5 g dose in specific situations.
How it is given
Your doctor or nurse will give you this medicine by injection or infusion into a vein.
After you have received Praxbind, your doctor will decide on the continuation of your treatment to prevent blood clot formation.
Pradaxa can be given again 24 hours after Praxbind administration.
If you are given too much (overdose)
As Praxbind is given to you under the supervision of your doctor, it is very unlikely that you will receive too much.
Like all medicines, this medicine may cause side effects, although not everybody gets them.
Until now, no side effects have been identified.
Tell your doctor or nurse if you notice any of the following and they worry you:
Tell your doctor or nurse as soon as possible if you experience any side effects during or after treatment with Praxbind,
so that these may be properly treated.
Ask your doctor or nurse to answer any questions you may have.
After being given Praxbind
Tell your doctor or nurse immediately if you notice any of the following:
long or excessive bleeding
tiredness, headaches, dizziness and looking pale (signs of anaemia)
chest pain or being short of breath
red or dark brown urine
red or black bowel motions.
These are signs or symptoms of bleeding. You may need urgent medical attention.
Praxbind will be stored in the pharmacy or ward in a refrigerator at 2°C to 8°C.
Prior to use, the unopened vial may be kept at room temperature (25°C) for up to 48 hours if stored in the original package
to protect from light. The unopened vial may be kept at room temperature for up to 6 hours when exposed to light.
Once the solution has been removed from the vial, Praxbind can be kept at room temperature for up to 1 hour.
Each vial can only be used once and unused contents of opened vials must be discarded.
What it looks like
Praxbind is a clear to slightly opalescent, colourless to slightly yellow solution. Praxbind is supplied in a 50 mL glass
vial, closed with a rubber stopper and secured with an aluminium flip-off cap.
Praxbind is available in packs of 2 vials.
Each 50 mL vial of Praxbind contains 2.5 g of idarucizumab. It also contains acetic acid-glacial, polysorbate 20, sodium acetate
trihydrate, sorbitol and water for injection.
Praxbind is supplied in Australia by:
Boehringer Ingelheim Pty Limited
ABN 52 000 452 308
78 Waterloo Road
North Ryde NSW 2113
This leaflet was prepared in May 2016.
® Praxbind is a registered trade mark of Boehringer Ingelheim.
© Boehringer Ingelheim Pty Limited 2016
Australian Registration Number
AUST R 237761